Furthermore, we propose a strategy for the targeted disruption of the KLHL37-N-Myc complex, and suggest that RTA-408, an inhibitor of KLHL37, may serve as a potential pharmacological approach for the treatment of patients with MYCN-amplified neuroblastoma. The gene discussed is MYCN; the disease is neuroblastoma.